Tyzeka® (telbivudine) – Product Discontinuation

- On September 30, 2016, the FDA announced the discontinuation of Novartis' Tyzeka (telbivudine) 600 mg tablets.
    - The discontinuation is not due to manufacturing, product quality, safety, or efficacy concerns.
    - Generic equivalents are not available; however, other therapeutic alternatives are available. Patients should speak to their healthcare provider regarding their hepatitis B therapy.
- Tyzeka is indicated for the treatment of chronic hepatitis B in adult patients with evidence of viral replication and either evidence of persistent elevations in serum aminotransferases (ALT or AST) or histologically active disease.
- For additional questions, contact Novartis at **1-888-669-6682**.

Action Plan

- Information regarding Tyzeka will be posted on the optumrx.com portals.